Trial Profile
Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Tofogliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 27 Jul 2022 Primary endpoint (The improvement in histologic features of NAFLD) has been met, according to Results published in the Diabetes Care.
- 27 Jul 2022 Results published in the Diabetes Care
- 25 Sep 2020 Results comparing the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors and sulfo- nylureas, which lower glucose levels with decreases and increases in circulating levels of insulin, respectively, in patients with type 2 diabetespresented at the 56th Annual Meeting of the European Association for the Study of Diabetes